Jia D - Search Results

1

Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.

Lu X, Zhan X, Xia G, Wang F, Lv M, Liu R, Liu Y, Zi C, Li G, Wang R, Li J, Yuan F, Jia D. Lu X, et al. Among authors: jia d. Mol Pharm. 2025 Jan 6;22(1):284-294. doi: 10.1021/acs.molpharmaceut.4c00891. Epub 2024 Dec 2. Mol Pharm. 2025. PMID: 39620978

2

Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.

Jia D, Yang Y, Yuan F, Fan Q, Wang F, Huang Y, Song H, Hu P, Wang R, Li G, Liu R, Li J. Jia D, et al. Int J Pharm. 2020 Aug 30;586:119541. doi: 10.1016/j.ijpharm.2020.119541. Epub 2020 Jun 13. Int J Pharm. 2020. PMID: 32544521

3

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.

Jia D, Wang F, Lu Y, Hu P, Wang R, Li G, Liu R, Li J, Liu H, Fan Q, Yuan F. Jia D, et al. Int J Pharm. 2022 May 25;620:121746. doi: 10.1016/j.ijpharm.2022.121746. Epub 2022 Apr 12. Int J Pharm. 2022. PMID: 35427745

4

Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.

Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F. Jia D, et al. J Pharm Sci. 2022 Feb;111(2):450-457. doi: 10.1016/j.xphs.2021.09.018. Epub 2021 Sep 20. J Pharm Sci. 2022. PMID: 34547305

5

Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors.

Liu H, Jia D, Yuan F, Wang F, Wei D, Tang X, Tian B, Zheng S, Sun R, Shi J, Fan Q. Liu H, et al. Among authors: jia d. Int J Pharm. 2022 Apr 5;617:121609. doi: 10.1016/j.ijpharm.2022.121609. Epub 2022 Feb 22. Int J Pharm. 2022. PMID: 35217073

6

ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors.

Jia D, Liu H, Zheng S, Yuan D, Sun R, Wang F, Li Y, Li H, Yuan F, Fan Q, Zhao Z. Jia D, et al. Mol Pharm. 2023 Jan 2;20(1):427-437. doi: 10.1021/acs.molpharmaceut.2c00708. Epub 2022 Oct 31. Mol Pharm. 2023. PMID: 36315025

7

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.

Wang H, Jia D, Yuan D, Yin X, Yuan F, Wang F, Shi W, Li H, Zhu LM, Fan Q. Wang H, et al. Among authors: jia d. J Nanobiotechnology. 2021 May 13;19(1):138. doi: 10.1186/s12951-021-00885-6. J Nanobiotechnology. 2021. PMID: 33985511 Free PMC article.

8

ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.

Jia D, Zhao S, Liu H, Zhan X, Zhou Z, Lv M, Tang X, Guo W, Li H, Sun L, Zhong Y, Tian B, Yuan D, Tang X, Fan Q. Jia D, et al. Int J Biol Macromol. 2024 Jun;269(Pt 2):132058. doi: 10.1016/j.ijbiomac.2024.132058. Epub 2024 May 3. Int J Biol Macromol. 2024. PMID: 38704065

9

Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.

Nie Q, Jia D, Yang H, Feng Y, Fan Q, Shi Q, Wan L, Lu X. Nie Q, et al. Among authors: jia d. Mol Pharm. 2017 Feb 6;14(2):502-512. doi: 10.1021/acs.molpharmaceut.6b00964. Epub 2017 Jan 12. Mol Pharm. 2017. PMID: 28029256

10

Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.

Su T, Yang H, Fan Q, Jia D, Tao Z, Wan L, Lu X. Su T, et al. Among authors: jia d. Int J Pharm. 2016 Feb 29;499(1-2):195-204. doi: 10.1016/j.ijpharm.2015.12.069. Epub 2016 Jan 2. Int J Pharm. 2016. PMID: 26752086

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,964 results

Search Page

Filters